Literature DB >> 35174510

NR4A nuclear receptors in T and B lymphocytes: Gatekeepers of immune tolerance.

Ryosuke Hiwa1,2, Jeremy F Brooks1, James L Mueller1, Hailyn V Nielsen1, Julie Zikherman1.   

Abstract

Random VDJ recombination early in T and B cell development enables the adaptive immune system to recognize a vast array of evolving pathogens via antigen receptors. However, the potential of such randomly generated TCRs and BCRs to recognize and respond to self-antigens requires layers of tolerance mechanisms to mitigate the risk of life-threatening autoimmunity. Since they were originally cloned more than three decades ago, the NR4A family of nuclear hormone receptors have been implicated in many critical aspects of immune tolerance, including negative selection of thymocytes, peripheral T cell tolerance, regulatory T cells (Treg), and most recently in peripheral B cell tolerance. In this review, we discuss important insights from many laboratories as well as our own group into the function and mechanisms by which this small class of primary response genes promotes self-tolerance and immune homeostasis to balance the need for host defense against the inherent risks posed by the adaptive immune system.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Nr4a1zzm321990; zzm321990Nr4a3zzm321990; B cell tolerance; NOR1; NUR77; T cell tolerance; anergy; clonal diversity; immunodominance; negative selection; self-reactivity

Mesh:

Substances:

Year:  2022        PMID: 35174510     DOI: 10.1111/imr.13072

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  2 in total

1.  Many Achilles' heels of B and T cell tolerance.

Authors:  Roberta Pelanda; Julie Zikherman
Journal:  Immunol Rev       Date:  2022-03-18       Impact factor: 12.988

Review 2.  Therapeutic potential of NR4A1 in cancer: Focus on metabolism.

Authors:  Shan Deng; Bo Chen; Jiege Huo; Xin Liu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.